Cargando…
Inhibition of the hedgehog pathway for the treatment of cancer using Itraconazole
Itraconazole (ITZ) is an anti-fungal drug that has been used in clinical practice for nearly 35 years. Recently, numerous experiments have shown that ITZ possesses anti-cancer properties. The Hedgehog (Hh) pathway plays a pivotal role in fundamental processes, including embryogenesis, structure, mor...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6711563/ https://www.ncbi.nlm.nih.gov/pubmed/31692536 http://dx.doi.org/10.2147/OTT.S223119 |
_version_ | 1783446539783372800 |
---|---|
author | Li, Ke Fang, Dengyang Xiong, Zuming Luo, Runlan |
author_facet | Li, Ke Fang, Dengyang Xiong, Zuming Luo, Runlan |
author_sort | Li, Ke |
collection | PubMed |
description | Itraconazole (ITZ) is an anti-fungal drug that has been used in clinical practice for nearly 35 years. Recently, numerous experiments have shown that ITZ possesses anti-cancer properties. The Hedgehog (Hh) pathway plays a pivotal role in fundamental processes, including embryogenesis, structure, morphology and proliferation in various species. This pathway is typically silent in adult cells, and inappropriate activity is linked to various tumor types. The most important mechanism of ITZ in the treatment of cancer is inhibition of the Hh pathway through the inhibition of smoothened receptors (SMO), glioma-associated oncogene homologs (GLI), and their downstream targets. In this review, we discuss the mechanisms of ITZ in the treatment of cancer through inhibition of the Hh pathway, which includes anti-inflammation, prevention of tumor growth, induction of cell cycle arrest, induction of apoptosis and autophagy, prevention of angiogenesis, and drug resistance. We also discuss the clinical use of ITZ in many types of cancers. We hope this review will provide more information to support future studies on ITZ in the treatment of various cancers. |
format | Online Article Text |
id | pubmed-6711563 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-67115632019-11-05 Inhibition of the hedgehog pathway for the treatment of cancer using Itraconazole Li, Ke Fang, Dengyang Xiong, Zuming Luo, Runlan Onco Targets Ther Review Itraconazole (ITZ) is an anti-fungal drug that has been used in clinical practice for nearly 35 years. Recently, numerous experiments have shown that ITZ possesses anti-cancer properties. The Hedgehog (Hh) pathway plays a pivotal role in fundamental processes, including embryogenesis, structure, morphology and proliferation in various species. This pathway is typically silent in adult cells, and inappropriate activity is linked to various tumor types. The most important mechanism of ITZ in the treatment of cancer is inhibition of the Hh pathway through the inhibition of smoothened receptors (SMO), glioma-associated oncogene homologs (GLI), and their downstream targets. In this review, we discuss the mechanisms of ITZ in the treatment of cancer through inhibition of the Hh pathway, which includes anti-inflammation, prevention of tumor growth, induction of cell cycle arrest, induction of apoptosis and autophagy, prevention of angiogenesis, and drug resistance. We also discuss the clinical use of ITZ in many types of cancers. We hope this review will provide more information to support future studies on ITZ in the treatment of various cancers. Dove 2019-08-23 /pmc/articles/PMC6711563/ /pubmed/31692536 http://dx.doi.org/10.2147/OTT.S223119 Text en © 2019 Li et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Li, Ke Fang, Dengyang Xiong, Zuming Luo, Runlan Inhibition of the hedgehog pathway for the treatment of cancer using Itraconazole |
title | Inhibition of the hedgehog pathway for the treatment of cancer using Itraconazole |
title_full | Inhibition of the hedgehog pathway for the treatment of cancer using Itraconazole |
title_fullStr | Inhibition of the hedgehog pathway for the treatment of cancer using Itraconazole |
title_full_unstemmed | Inhibition of the hedgehog pathway for the treatment of cancer using Itraconazole |
title_short | Inhibition of the hedgehog pathway for the treatment of cancer using Itraconazole |
title_sort | inhibition of the hedgehog pathway for the treatment of cancer using itraconazole |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6711563/ https://www.ncbi.nlm.nih.gov/pubmed/31692536 http://dx.doi.org/10.2147/OTT.S223119 |
work_keys_str_mv | AT like inhibitionofthehedgehogpathwayforthetreatmentofcancerusingitraconazole AT fangdengyang inhibitionofthehedgehogpathwayforthetreatmentofcancerusingitraconazole AT xiongzuming inhibitionofthehedgehogpathwayforthetreatmentofcancerusingitraconazole AT luorunlan inhibitionofthehedgehogpathwayforthetreatmentofcancerusingitraconazole |